CDK Inhibitors for Specialized Operational Environments

Publication ID: 24-11857552_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “CDK Inhibitors for Specialized Operational Environments,” Published Technical Disclosure No. 24-11857552_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857552_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,552.

Summary of the Inventive Concept

The inventive concept adapts CDK inhibitors for specific, narrow markets or unique operational environments, such as high-security bioresearch facilities, disaster relief, extreme weather conditions, high-altitude research, and emergency medical response.

Background and Problem Solved

The original patent disclosed CDK inhibitors for general therapeutic use, but did not address the unique challenges and requirements of specialized operational environments. The new inventive concept addresses these limitations by providing tailored solutions for these specific contexts.

Detailed Description of the Inventive Concept

The inventive concept comprises a system, method, composition, or kit that incorporates the CDK inhibitors disclosed in the original patent, adapted for use in specialized operational environments. For example, the system for high-security bioresearch facilities comprises a secure storage unit for storing the compound, while the method for disaster relief includes administering the compound to a patient in need of CDK inhibition and providing a portable medical unit for remote patient care. The composition for extreme weather conditions includes a weather-resistant packaging material, and the kit for high-altitude research includes a portable laboratory unit for on-site analysis.

Novelty and Inventive Step

The new claims are novel and non-obvious compared to the original patent because they introduce specific, specialized variations and niche solutions that were not anticipated or disclosed in the original patent. The inventive step lies in the recognition of the need for tailored CDK inhibitors for unique operational environments and the development of adapted solutions that address these specific challenges.

Alternative Embodiments and Variations

Alternative embodiments and variations of the inventive concept could include adapting the CDK inhibitors for use in other specialized operational environments, such as space exploration, underwater research, or search and rescue operations. Additionally, the inventive concept could be modified to incorporate other therapeutic agents or technologies to enhance its effectiveness in these contexts.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in various industries, including biotechnology, pharmaceuticals, and medical devices. The target market includes organizations and institutions operating in specialized operational environments, such as government agencies, research institutions, and private companies. The inventive concept could also be licensed or partnered with other companies to expand its reach and impact.

Original Patent Information

Patent NumberUS 11,857,552
Title4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors
Assignee(s)CARRICK THERAPEUTICS LIMITED